ARTICLE | Clinical News
RE-024 regulatory update
May 18, 2015 7:00 AM UTC
FDA granted Orphan Drug designation to RE-024 from Retrophin to treat pantothenate kinase-associated neurodegeneration (PKAN). The product is in Phase I testing. RE-024 is a phosphopantothenate molecu...